01 Shift Towards Non-Invasive Vagus Nerve Stimulation DevicesThe global market is witnessing a notable shift toward non-invasive and wearable devices as safer and more accessible alternatives to traditional implantable systems. In a recent development, Tivic Health reported successful clinical trial results showing that its non-invasive VNS device produces positive autonomic and neurological effects.This trend highlights how non-invasive neuromodulation is expanding the adoption of vagus nerve stimulation therapies, transforming VNS from a primarily implant-based treatment to a more widely accessible therapeutic option.
02 Integration of Digital Health and Remote Monitoring with VNS TherapyThe global market is increasingly integrating with digital health platforms and remote monitoring tools, improving treatment adherence and patient engagement. Previously, patients faced challenges in maintaining consistent therapy due to reliance on in-clinic sessions and limited access to monitoring tools. Today, digital solutions, such as electroCore, Inc.’s direct-to-consumer mobile app-enabled non-invasive VNS device, allow patients to manage therapy from home while receiving real-time feedback and guidance.Such integrated approaches are expanding home-based care, enhancing patient engagement, and making VNS therapy more accessible, reflecting a shift toward patient-centric, technology-enabled neuromodulation.
01 Growing new Indication Approvals for VNS DevicesThe expansion of vagus nerve stimulation into inflammatory conditions, such as rheumatoid arthritis, is emerging as a key growth driver for the vagus nerve stimulation market. For example, in July 2025, the U.S. Food and Drug Administration (FDA) approved the SetPoint System, an implantable VNS device for treating rheumatoid arthritis. This regulatory approval for a new clinical indication is driving broader adoption of VNS devices, thereby accelerating overall market growth.
01 High Cost of VNS Devices and ProceduresA key restraint in the market is the high cost of devices and implantation procedures, which limit patient access in low-income countries. According to Neurology Journals, the initial cost of a VNS device is approximately USD 10,000, with additional expenses for surgery and device programming. Consequently, these high treatment costs hinder widespread adoption of VNS therapy and pose a challenge to overall market growth.
01 Growing use of VNS Therapy for Post-Surgical Recovery and RehabilitationAn emerging opportunity in the market is the use of VNS therapy to accelerate post-surgical recovery and rehabilitation. Recent studies indicate that VNS promotes neuroplasticity and improves motor recovery in patients undergoing procedures such as stroke-related surgeries. Therefore, this specialized application is expected to open new avenues for growth, positioning VNS as a valuable adjunctive therapy in post-operative care during the forecast period.
March 2026 LivaNova expanded its vagus nerve stimulation technology portfolio with advanced neuromodulation solutions designed for the treatment of neurological disorders and improving patient outcomes.
September 2025 Medtronic introduced enhanced neuromodulation technologies with improved stimulation capabilities to support the management of neurological conditions.
May 2025 Abbott expanded its neuromodulation portfolio with advanced implantable stimulation solutions focused on neurological disorder treatment and personalized patient care.